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Riboﬂavin transporter deﬁciency (formerly known as Brown-Vialetto-Van Laere [BVVL] or
Fazio-Londe syndrome) is a neurodegenerative disorder characterized by progressive bulbar
palsy with sensorineural deafness or bulbar hereditary neuropathy.1 It is caused by mutations in
the riboﬂavin transporter genes SLC52A2 (RFVT2) or SLC52A3 (RFVT3).2,3 It is a rare
syndrome with approximately 70 cases reported worldwide, with molecular diagnoses of
RFVT2 or RFVT3.1,4 We have previously described the ﬁrst Brazilian family with a clinical
diagnosis of BVVL.5
In this report, we extend the clinical spectrum associated with this family and describe a new
mutation related to the metabolism of riboﬂavin.
Case report
The proband was a previously healthy woman aged 34 years, who presented with hearing and
vision loss in the last 6 months (ﬁgure, A). She was disturbed by facial pain, numbness in the left
hemiface, diﬃculty moving her tongue, dysphagia, weight loss, and bilateral foot drop.
Examination demonstrated bilateral optic atrophy, normal ocular movements, bilateral facial
paresis, atrophic tongue, and ﬂaccid dysarthria. Reﬂexes were brisk except for ankle reﬂexes that
were absent. Plantar responses were indiﬀerent. All sensory modalities were normal. Strength
was globally diminished with important distal impairment and foot drop. As dysphagia
and dyspnea progressed, a feeding tube was placed and noninvasive ventilation support was
initiated. At that time, she was quadriplegic and could not walk.
Electroneuromyography demonstrated cervical and acute lumbar denervation, with chronic
neurogenic changes. Audiologic evaluation demonstrated neurosensorial loss.
The patient was the eldest sibling of a consanguineous marriage. She had 3 maternal aunts, also
sisters from a consanguineous marriage, with a probable diagnosis of BVVL syndrome.5
The patient was started on empiric treatment with riboﬂavin (1,800 mg per day), and within 6
months of therapy, she could walk with a cane; the feeding tube and noninvasive ventilation
were withdrawn (ﬁgure, B–G). Electroneuromyography was performed after B2 treatment and
demonstrated low CMAP amplitudes and persistence of recent denervation (ﬁgure e-1, http://
links.lww.com/NXG/A17).
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Methods
The genetic study of the patient and both parents was conducted
after written informed consent was obtained. Whole-exome se-
quencing (WES) was performed in the index case, and whole-
genome genotyping (WGG) was used to identify large tracts of
homozygosity in the trio, given the apparent autosomal recessive
pattern of inheritance of the disease in the family and the presence
of several loops of consanguinity. The 3 samples were genotyped
at the whole-genome level using Illumina HumanOmniExpress
Bead chips, and results were analyzed with GenomeStudio.
Results
By analyzing the variability identiﬁed by WES in genes pre-
viously known to cause riboﬂavin transporter deﬁciency, we
identiﬁed a novel homozygous insertion in SLC52A3
(ENST00000217254(SLC52A3):c.1232_1233insCTACGC
TTCCCTCCCGGCCCCGCAGGTGGCCTCGTGGGT-
GCTTTTCAGCGGCTGCCTCAG; p.Ser411_Tyr412in-
sTyrAlaSerLeuProAlaProGlnValAlaSerTrpValLeuPheSerGly
CysLeuSer). The mutation was conﬁrmed to be present in
homozygosity in the index and was found in heterozygosity in
both parents using Sanger sequencing. In addition, WGG
revealed a large (1.5 Mb) homozygous region encompassing
the SLC52A3 locus (chromosome 20: 643,919–2,146,580
Mb) that was not present in either parent. Consequently, we
tested the phenotypically aﬀected aunt (II.10), and she pre-
sented themutation in homozygosity (ﬁgure e-2, http://links.
lww.com/NXG/A18).
The mutation found is neither present in homozygosity in
population databases of genetic variability (ExAC and gno-
mAD), nor have we identiﬁed it in our in-house sequencing
data from healthy controls and other diseases (n > 6,000).
Discussion
Both SCL52A3 and SCL52A2 are riboﬂavin transporters. Ri-
boﬂavin is a precursor of ﬂavin mononucleotide and ﬂavin
adenine dinucleotide, which are important cofactors for en-
ergy metabolism. Since the description of these 2 genes re-
lated to riboﬂavin transporter deﬁciency, the perspective
about this disease has changed signiﬁcantly.2,4,6 However, the
mechanisms by which the disrupted proteins lead to the dis-
ease are still to be fully understood.
Motor neuron disease, neurosensorial deafness, optic neurop-
athy, and the involvement of cranial nerves are common in
both genotypes.4,7 Nevertheless, some phenotypic diﬀerences
have been described: RFVT2mutations present predominantly
upper limb weakness and sensory ataxia; such ﬁndings are not
commonly seen in patients with RFVT3 mutations.7
Here, we report a Brazilian patient with late-onset and un-
characteristic acute and severe presentation, demonstrating
some phenotypic heterogeneity within a family.5 Themutation,
a homozygous insertion of 60 bp in SCL52A3, has not been
previously described as the cause of riboﬂavin transporter de-
ﬁciency. So far, response to riboﬂavin therapy was documented
Figure Family pedigree and clinical improvement with ri-
boflavin treatment
(A) The proband is marked with an arrow. This is a family member recently
studied, while subjects II.8, II.9, II.10, and III.3 were previously described in
Arq Neuropsiquiatr 2007;65(1):32–35. Squares represent males, and circles
represent females. Black symbols represent affected family members. The
proband’s mother and father were found to be heterozygous for
the SLC52A3 insertion (+/−). Themutation was found in homozygosity in the
proband (+/+) and her aunt. (B and C) Proband’s interosseal atrophy. (D and
E) Improvement in facial weakness and (F and G) tongue atrophy after ini-
tiation of 1,800 mg of riboflavin.
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in 11 patients harboring mutations in RFVT3. Of them, 9
patients demonstrated some response and 2 remained stable.4,6
Some authors argue that response tends to be better and more
rapid when earlier treatment is started. Riboﬂavin dose re-
position is unknown, and treatment, although generally eﬃ-
cient, is empirical. In addition, there is still no evidence to
reassure that treatment would prevent the occurrence of
symptoms indeﬁnitely. Despite all this, clinicians might be
aware of this potentially treatable condition and initiate ribo-
ﬂavin supplementation as soon as diagnosis is suspected.
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